Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $6.3B; returns 1 day -5.0%, 1 week -2.4%, 1 year +97.9%.

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's pipeline products include rilonacept for recurrent pericarditis and cardiac sarcoidosis. Their other products include KPL-1161 and Abiprubart.

Groups KNSA belongs to

• Biotechnology
• United Kingdom Companies
• Biopharmaceutical
• Healthcare
• Commercial Stage Biotech
• Cardiovascular Therapies
• Unmet Medical Needs
• Rare Diseases
• Autoimmune Diseases
• Clinical Stage Biotech

KNSA financial model: income statement, cash flow and balance sheet